NHS England agrees funding for hepatitis drug

NHS England has approved an £18.7 million investment in a new drug for the treatment of hepatitis C. Around 500 patients with acute liver failure, and/or awaiting liver transplantation, are expected to benefit from the decision to fund Sofosbuvir.

Current estimates indicate that around 30% of people infected with chronic hepatitis C will develop cirrhosis of the liver which, in some cases, may prove fatal without a liver transplant. The recommendation of NHS England’s Clinical Priorities Advisory Group (CPAG) means that, while not yet NICEapproved, Sofosbuvir will be funded for those patients at significant risk of mortality or who require transplantation.

Latest Issues

AfPP Annual National Conference

University of Warwick
8th - 9th August 2025

IGPP Annual Operating Theatres Show

Manchester, Etihad Stadium
11th September 2025

Clinical Engineering Conference

Stansted Radisson Blu
23rd September 2025

Infection Prevention 2025

Brighton Centre, UK
29th - 30th September 2025

CSC Autumn Meeting

Ramada Plaza, Wrexham
13th October 2025